Bladder cancer is a leading cause of cancer-associated deaths in developed countries. It is more common in developed than in developing countries and, for reasons that are still not well understood, it is three to four times more prevalent in males than in females. The disease is characterized by heterogeneous subtypes that have a range of disease outcomes, but the broad subgroups are non-muscle-invasive bladder cancer, which is more common and usually associated with a favourable prognosis, and muscle-invasive bladder cancer, which is less prevalent but typically associated with a relatively poor prognosis (for general reviews on bladder cancer see REFS 1-3). Notably, bladder cancer is one of the most costly cancers to treat, owing primarily to the considerable costs associated with life-long clinical management of patients with nonmuscle-invasive disease, as well as costs associated with caring for patients after surgical removal of the bladder 4 . Surprisingly, despite its prevalence and adverse impact on human health, bladder cancer has been understudied compared with other cancers and remains under-represented by informative in vivo models, particularly genetically engineered mouse (GEM) models. However, the tide is now changing with the recent generation of new mouse models of bladder cancer, as well as the recent elucidation of molecular alterations that are prevalent in bladder cancer, which provide new avenues for developing models of disease-relevant genes and/or pathways. Here we introduce key concepts that are essential for the generation of informative mouse models and their effective translation to human bladder cancer. In addition, we review the status of mouse models of bladder cancer that are currently available and discuss prospects for their future development.
Bladder cancer is a leading cause of cancer-associated deaths in developed countries. It is more common in developed than in developing countries and, for reasons that are still not well understood, it is three to four times more prevalent in males than in females. The disease is characterized by heterogeneous subtypes that have a range of disease outcomes, but the broad subgroups are non-muscle-invasive bladder cancer, which is more common and usually associated with a favourable prognosis, and muscle-invasive bladder cancer, which is less prevalent but typically associated with a relatively poor prognosis (for general reviews on bladder cancer see . Notably, bladder cancer is one of the most costly cancers to treat, owing primarily to the considerable costs associated with life-long clinical management of patients with nonmuscle-invasive disease, as well as costs associated with caring for patients after surgical removal of the bladder 4 . Surprisingly, despite its prevalence and adverse impact on human health, bladder cancer has been understudied compared with other cancers and remains under-represented by informative in vivo models, particularly genetically engineered mouse (GEM) models. However, the tide is now changing with the recent generation of new mouse models of bladder cancer, as well as the recent elucidation of molecular alterations that are prevalent in bladder cancer, which provide new avenues for developing models of disease-relevant genes and/or pathways. Here we introduce key concepts that are essential for the generation of informative mouse models and their effective translation to human bladder cancer. In addition, we review the status of mouse models of bladder cancer that are currently available and discuss prospects for their future development.
Biology and lineage relationships of the bladder
The bladder comprises a specialized epithelium -the urothelium -that is encapsulated by the lamina propria, which in turn is surrounded by a thick layer of smooth muscle -the detrusor muscle (or muscularis propria) -that forms the bladder wall 5, 6 (FIG. 1) . The urothelium includes three cell types: basal cells, which are relatively small cuboidal cells that express p63 and high molecular weight cytokeratins, such as CK5 (also known as KRT5) and CK14 (also known as KRT14); intermediate cells, which also express p63 and high molecular weight cytokeratins, although at lower levels than the basal layer; and superficial cells (also called umbrella cells), which express uroplakin proteins and low molecular weight cytokeratins, such as CK18 (also known as KRT18) and CK20 (also known as KRT20) [7] [8] [9] [10] [11] . Among these, the superficial cells are the most highly specialized, relatively large and often polynucleate. They have polarized membranes that are insoluble, and specialized structures on their apical surface, known as the asymmetric unit membrane (AUM), which comprises uroplakin proteins and provides a barrier against reabsorption of urine (hence the term umbrella cells) 12 .
The bladder urothelium has one of the slowest cell-turnover rates of any adult tissue 13, 14 . However, in response to injury -for example, as a consequence of bacterial infection or exposure to toxins -the urothelium undergoes rapid proliferation and ultimately regenerates an intact urothelium 15, 16 , although the actual response may depend on the specific inducing agent (see REF. 17 and below). The implication of these observations is that the adult urothelium contains stem or progenitor cells that are capable of its regeneration. 
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Lamina propria
The layer of connective tissue that underlies the urothelium.
Detrusor muscle
The layer of smooth muscle that lines the bladder and controls the elimination of urine.
Uroplakin proteins
Transmembrane proteins that comprise the asymmetric unit membrane on the lumen-facing side of the umbrella cells, providing a barrier against the entry of urine.
Papillary tumours
Extrusions of the urothelium into the bladder lumen without invasion of the muscle layer.
Carcinoma in situ (CIS) . A flattened malignant transformation of the urothelium that is presumed to be a precursor of muscle-invasive bladder cancer.
Such stem or progenitor cells have long been thought to reside in the basal cell layer. In particular, lineage tracing of mouse bladder following pathogen-induced regeneration showed that basal cells give rise to all urothelial cell types, supporting the idea that they are progenitor cells 18 . However, several lines of evidence, based on analyses of both human and mouse bladder, suggest that the urothelium may have independent lineages that are generated by distinct progenitors 19 . Such a multiple progenitor model has been supported by an alternative lineage tracing study following chemically induced regeneration, which concluded that umbrella cells are derived from intermediate rather than basal cells 20 . In addition, analyses of labelretaining cells in mouse bladder during development as well as after pathogen-induced regeneration also support a multiple lineage model 11, 21 ; notably, during development the progenitors are concentrated in the trigone 11 , a specialized structure in the bladder. Furthermore, mice harbouring a germline deletion of Trp63 (the gene encoding p63), which is expressed in basal but not umbrella cells, lack basal and intermediate cells but have a superficial cell layer 22, 23 . In addition to these studies of mouse bladder, results from analyses of clonal relationships in human bladder, inferred from analyses of mitochondrial DNA, also support a model in which the bladder has multiple progenitors 24 . Clearly, lineage relationships within the bladder urothelium are far from resolved.
Bladder cancer: a primer for the mouse modeller The term 'bladder cancer' refers to a heterogeneous set of diseases with a spectrum of pathologies and expected prognoses. However, most (approximately 90%) are urothelial carcinomas, which are the subject of this Review and are referred to simply as bladder cancers here (FIG. 2) ; the remainder (approximately 10%) include primary squamous cell carcinoma, adenocarcinoma, small cell carcinoma and sarcomatoid carcinoma 1, 3, 25 , and are not discussed further in this Review.
As mentioned, non-muscle-invasive tumours account for the vast majority of bladder cancers (approximately 75%), most of which have a relatively favourable prognosis 1, 2 . These can be subgrouped further into low-grade (mainly superficial tumours, also known as papillary tumours) and high-grade tumours (which include a subset of superficial tumours as well as carcinoma in situ (CIS)) (FIG. 2) . As their name implies, superficial (or papillary) tumours grow into the bladder lumen but do not invade the muscle layer, whereas CIS is characterized by a flattened layer of dysplastic cells that is the presumed main precursor of invasive bladder cancer 26, 27 . In contrast to the non-muscle-invasive disease, muscle-invasive bladder cancer accounts for approximately 25% of cases and has a relatively poor prognosis. In particular, patients with muscle-invasive tumours have a 5-year survival of approximately 50%, and patients with muscleinvasive tumours that have metastasized have a 5-year survival of approximately 15% only (REFS 1,3). Below, we discuss key clinical aspects of bladder cancer that impact the generation of informative mouse models.
Cells of origin of bladder cancer and their relationship to bladder cancer subtypes. Various studies in humans and mice have implicated basal cells as cells of origin of bladder cancer 19 . In the mouse, for example, analyses of lineage tracing in a carcinogen-based model concluded that basal cells can serve as cells of origin for bladder cancer 28 . In humans, isolation of putative stem cells based on the expression of cell-surface markers followed by growth in xenograft models has shown that such stem cells are enriched for basal cells, particularly the most aggressive tumour subtypes [29] [30] [31] . Furthermore, analysis of 
Intravesical therapy
Delivery of interventional or therapeutic agents directly to the bladder lumen.
Bacillus Calmette-Guerin (BCG). A form of immunotherapy; a front-line intravesical treatment for high-risk non-muscle-invasive bladder cancer.
Cystectomy
Surgical removal of the bladder; the front-line treatment for muscle-invasive bladder cancer.
gene expression profiling of invasive bladder cancer has categorized a basal-like subtype with a more aggressive phenotype, and a luminal-like subtype with a less aggressive phenotype [32] [33] [34] [35] . Although it is not necessarily the case that the basal subtype originates from basal cells, this observation is certainly consistent with the concept that basal cells can serve as cells of origin of bladder cancer, particularly for more aggressive subtypes.
However, studies in both humans and mice have demonstrated alternative cells of origin that may give rise to distinct bladder cancer subtypes. In mice, for example, an alternative analysis of lineage tracing of a carcinogen-based model has shown that hetero geneous subtypes of bladder cancer can be attributed to distinct cells of origin 36 . In humans, analyses of gene signatures from subpopulations of normal urothelial cells support the idea that distinct subtypes of bladder cancer arise from distinct cells of origin 37 . Moreover, the gene expression profiling studies discussed above categorized distinct basal-like and luminal-like subtypes of bladder cancer [32] [33] [34] [35] ; although these are not necessarily indicative of multiple cells of origin, this is also not inconsistent with this concept. A precise understanding of the cells of origin of bladder cancer and their relationship to specific clinical subtypes is of paramount importance for generating informative mouse models of bladder cancer.
Therapy for bladder cancer. The treatment of bladder cancer, and its efficacy, varies profoundly depending on the clinical stage and associated risk factors 1, 3, 38, 39 (FIG. 2) .
The front-line treatment for non-muscle-invasive bladder cancer is transurethral resection (TUR) 39 , which has a high disease-free survival for low-grade disease, but a high rate of relapse for high-grade disease. Owing to the unique biology and tissue organization of the bladder, non-muscle-invasive bladder cancers can be treated locally (rather than systemically) by what is called intravesical therapy. In particular, the front-line treatment for patients with non-muscle-invasive bladder cancer who are at high risk of recurrence following TUR is intravesical delivery of bacillus Calmette-Guerin (BCG) 40, 41 , which is in fact a vaccine against tuberculosis that promotes immunoreaction against bladder cancer cells 42 . Patients who fail BCG treatment are candidates for cystectomy (surgical removal of the bladder), or alternatively for salvage intravesical therapy using chemo therapy regimens or targeted agents in an effort to preserve bladder function 43 (for example, see ClinicalTrials.gov identifier: NCT02202772).
Cystectomy, with or without neoadjuvant chemotherapy 44, 45 , is also the front-line treatment for muscleinvasive bladder cancer 39, 46 . Patients who undergo cystectomy have a 5-year survival ranging from 30% to 70%, depending on the stage of the tumour, and the inevitable requirement of urinary tract diversion results in a profound impairment in quality of life 47, 48 . Notably, cystectomy is not always a viable option for patients, and is not generally recommended for patients with metastatic bladder cancer, as it has very little chance of being curative. Instead, the standard of care for metastatic bladder cancer is a multidrug chemotherapy regimen consisting of methotrexate, vinblastine, adriamycin and cisplatin (known as MVAC) or, alternatively, gemcitabine plus cisplatin (known as GC). Both of these regimens have a low response rate (approximately 40% to 50%) and there is limited improvement in overall survival (approximately 12 to 15 months) 39 . Moreover, cisplatin-based chemotherapy is not an option for many elderly patients, who form a large subset of those with advanced bladder cancer, owing to the potential for kidney failure. Thus, treatment options for muscle-invasive bladder cancer are limited and, in striking contrast with therapy for many other cancers, have not improved substantially in recent years.
What are the causes of bladder cancer? Genomewide association studies have identified various lowpenetrance susceptibility loci associated with increased cancer risk 49 , however bladder cancer is thought to arise primarily as a consequence of environmental exposures [50] [51] [52] [53] [54] . Indeed, the major risk factor for bladder cancer is smoking 50, 54 , and the relatively high incidence of bladder cancer in developed versus developing countries is thought to reflect the prevalence of smoking in developed countries. Carcinogens from tobacco smoke, as well as those associated with occupational hazards [51] [52] [53] , are presumed to promote bladder cancer by virtue of becoming concentrated in urine, in effect bathing the urothelium with carcinogens.
Interestingly, these associated risk factors cannot account fully for the approximately three-to fourfold difference in the incidence of bladder cancer in men versus women, particularly with respect to smoking 50 . The implication is that there may be fundamental differences in bladder physiology, and/or its development, that underlie the striking prevalence of bladder cancer in men. Notably, the epithelium of the bladder and that of the prostate, although highly specialized and distinct, share a common embryological origin, namely the urogenital sinus 55 . Thus, it has been proposed that the increased prevalence of bladder cancer in males versus females reflects, at least in part, androgen receptor function in bladder cancer 56 , as supported by recent analyses of GEM models 57, 58 .
Molecular subtypes of bladder cancer
Non-muscle-invasive versus muscle-invasive bladder cancer. Several lines of evidence support the general concept that the distinct clinical outcomes of low-grade non-muscle-invasive versus high-grade muscle-invasive bladder tumours reflect their distinct molecular causes and, as discussed above, potentially their distinct cells of origin. Indeed, certain molecular alterations, such as gain of function mutations in fibroblast growth factor receptor 3 (FGFR3), are prevalent in low-grade non-muscle-invasive bladder cancers, whereas other alterations, such as p53 loss or mutation, are prevalent in high-grade muscleinvasive bladder cancers 53, [59] [60] [61] [62] . Analyses of gene expression profiling [63] [64] [65] [66] [67] [68] and/or genomic alterations 65, [69] [70] [71] [72] [73] have supported the general concept that low-grade non-invasive bladder tumours are molecularly distinct from high-grade invasive bladder tumours, however it is difficult to reconcile fully a mutual-exclusivity model, considering that some superficial bladder tumours can progress to invasive disease. Furthermore, meta-analysis of expression profiling data from non-invasive and invasive bladder cancers failed to identify molecular subtypes that are clearly associated with pathological stage 74 . Recent whole-genome sequencing and transcriptome analyses comparing low-grade and high-grade bladder cancers support the idea that they evolve in parallel rather than in a mutually exclusive manner 75 . Thus, low-grade non-muscle-invasive and highgrade muscle-invasive bladder cancer may be more appropriately viewed as broadly distinct entities along a continuum of disease progression. In this framework, the actual phenotype and outcome may reflect the culmination of molecular alterations that tend to drive more-or less-aggressive phenotypes, distinct cells of origin (which may contribute to tumour aggressiveness), and potential interactions with exposure to environmental factors, such as tobacco smoke, carcinogens or inflammation.
Molecular alterations in muscle-invasive bladder cancer.
The Cancer Genome Atlas (TCGA) has reported recently a comprehensive molecular analysis of muscle-invasive bladder cancer 32 and, together with results from several additional whole-exome or whole-genome analyses [76] [77] [78] [79] [80] , this TCGA analysis has confirmed and extended the contribution of known genes and molecular pathways, and identified interesting new ones. In particular, as anticipated from many earlier studies, TCGA study found that TP53 (which encodes p53) is deleted and/or mutated in approximately 49% of muscle-invasive bladder cancers, and, more generally, that genes encoding members of the p53 -RB pathway are altered in most muscle-invasive bladder cancers. However, surprisingly, FGFR3 mutations -which had long been associated almost exclusively with non-muscle-invasive bladder cancer -were found to be relatively common (approximately 12%) in muscle-invasive disease 32 . Furthermore, TCGA study, together with integrative analyses of high-grade bladder tumours 81 and analyses of patients who are 'exceptional responders' to targeted therapy 82, 83 , have demonstrated the relevance of the PI3K-mTOR and receptor tyrosine kinase (RTK)-RAS-MAPK signalling pathways, and support the rationale for therapeutic targeting of these 'actionable' signalling pathways for the treatment of advanced bladder cancer. In particular, 42% or 44% of muscle invasive tumours were found to have alterations of genes associated with PI3K-mTOR signalling or RTK-RAS-MAPK pathways, respectively, including genes such as PIK3CA, tuberous sclerosis 1 (TSC1), TSC2, AKT3, FGFR3, epidermal growth factor receptor (EGFR) and ERBB2 (also known as HER2) 32 . Indeed, there has been a long standing rationale for therapeutic targeting of RTK-RAS-MAPK signalling, as HRAS was identified originally in bladder cancer cells [84] [85] [86] , but members of the RAS family have proven difficult to target. Thus, clinical efforts have been focused on targeting relevant downstream pathways, such as FGFR3 (REF. 87) and EGFR 88 (for example, see ClinicalTrials.gov identifiers: NCT01732107 and NCT01953926). Furthermore, current clinical trials targeting the PI3K-mTOR pathway with various mTOR inhibitors such as temsirolimus or everolimus (also known as RAD001) are now underway (for example, see ClinicalTrials.gov identifiers: NCT01827943, NCT00805129 and NCT02009332).
In addition, TCGA identified several genes that are frequently (occurring in more than 10% of patients) altered in bladder cancer but that had not been implicated previously in bladder cancer (and in some cases not in any cancer), including MLL2 (also known as KMT2D), cyclin-dependent kinase inhibitor 1A (CDKN1A), excision repair cross-complementation group 2 (ERCC2) and stromal antigen 2 (STAG2) 32 . Also notable is the prevalence of alterations of epigenetic regulatory genes, including UTX (also known as KDM6A), MLL2, CREB binding protein (CREBBP), and AT rich interactive domain 1A (ARID1A) 32, 76 , thus providing new avenues for therapeutic targeting of invasive bladder cancer. Interestingly, TCGA study, along with metaanalyses of TCGA datasets representing 12 distinct cancers 89, 90 , found that bladder cancer has among the highest number of mutations per DNA megabase of any cancer.
Consistent with this observation, whole-genome sequencing of five muscle-invasive bladder tumours that have mutated TP53 found a profound level of nucleotide alterations as well as chromothripsis 77 , which refers to the shattering and reassembly of chromosomes as a consequence of genomic instability. This may be a reflection of the unusual susceptibility of the urothelium to environmental carcinogens (discussed above).
Modelling bladder cancer in mice
Recent studies have advanced our conceptual understanding of the biological, molecular and environmental factors associated with bladder cancer, but this knowledge has not yet advanced to the point of impacting patient care. In fact, the field is still grappling with major uncertainties regarding the nature and complexity of bladder cancer subtypes, how they are related to each other, and how they can best be treated to improve patient outcomes. Our understanding of these issues would benefit greatly from the availability of mouse models that represent specific bladder cancer phenotypes or subtypes accurately and that are based on relevant genes, pathways and/or processes that are associated with bladder cancer (TABLE 1) . However, in contrast to many other cancer types, for which there has 
Genetic risk factors
• Model genetic susceptibility loci been a veritable explosion in the generation of mouse models over the past two decades, bladder cancer is relatively under-represented by mouse models, particularly GEM models. At present, mouse models of bladder cancer include carcinogen-based models, in which tumours arise following the treatment of mice (or rats) with carcinogens, various types of engraftment models, in which cells or tissues are grown in recipient hosts, and GEM models, based on activation or inactivation of gene function in the bladder (TABLE 2 ). An important distinction between these types of models is that carcinogen-based and GEM models are autochthonous, which means that tumours originate in the bladder, whereas graft models are nonautochthonous, as they are implanted into recipient hosts. Notably, graft-recipient mice are usually immunodeficient, which is relevant given the known importance of the immune system for cancer progression and metastasis 91 . However, the considerable advantage of engraftment models is their relative ease and rapidity of generation, and their use in analyses of the functional relevance of candidate genes. Furthermore, although they are both autochthonous, tumours in carcinogenbased models are, by definition, induced by carcinogens, whereas those in GEM models arise following manipulation of specific genes. Thus, these different approaches to modelling bladder cancer in mice are highly complementary (TABLE 2) . In addition to the discussion below, we refer the reader to recent reviews of bladder cancer cell lines and in vivo models of bladder cancer [92] [93] [94] .
Carcinogen models
The classic model of bladder cancer is based on chemical carcinogenesis of the urothelium, which conceptually mimics environmental exposures that are known to be a leading cause of bladder cancer. The induction of bladder cancer through the application of carcinogens was first introduced for use in rats in the 1960s , and since then several carcinogens and various species have been used, including mice, rats and dogs 98 . Notably, carcinogen models were among the first preclinical models to evaluate chemotherapy for bladder cancer 99 , and they continue to provide informative models for understanding processes involved in cancer progression and for elucidating cancer subtypes.
Currently, the majority of carcinogen-induced mouse models of bladder cancer use N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN), which is delivered in drinking water. BBN is highly relevant to human bladder cancer because it is very similar to the major carcinogen associated with tobacco smoke 100 . Although delivered systemically (rather than to the bladder directly), the urothelium is particularly susceptible to BBN treatment, as evident from analyses of the mutagenesis spectrum across various tissues 101 . BBN-treated mice develop a range of bladder cancer phenotypes, including hyperplasia, dysplasia, CIS and muscle-invasive bladder cancer, as well as metastases in certain strain backgrounds 102 . Notably, mutations of relevant genes such as Trp53 (which encodes p53) 102 , and the molecular profiles of tumours from BBN-treated mice 103, 104 , share similarities with those of human invasive bladder cancer. Furthermore, treatment of GEM models with BBN has the advantage of exacerbating the consequences of loss-or gain-of-function phenotypes (discussed below). In particular, a recent study of bladder tumours that arise following BBN-treatment of mice with or without heterozygous deletion of Trp53 showed that the range of bladder cancer phenotypes is influenced by the status of Trp53 (REF. 36 ).
Among their major advantages, carcinogen treatments simulate actual events that are known to give rise to bladder cancer in humans. In addition, these models are relatively straightforward to implement, and autochthonous tumours arise in immunocompetent mice. Among their disadvantages, despite the fact that the urothelium may be most susceptible to BBN treatment, BBN treatment is systemic and it is difficult to rule out the contribution of other tissues. Furthermore, tumour phenotypes and their temporal progression are highly heterogeneous in BBN-treated mice, and vary depending on species and strain background. Although this inherent heterogeneity may capture key elements of human bladder, it makes it difficult to implement preclinical studies or to model specific disease subtypes.
Engraftment models
Orthotopic and renal engraftment. Urothelial cancer cells can be engrafted orthotopically in mice or rats, such that tumours arise within the bladder of recipient hosts. First introduced in the 1970s (REF. 105 ), delivery of cancer cells into the bladder lumen has been used widely to model bladder cancer [106] [107] [108] [109] [110] . The recent introduction of ultrasound-guided implantation of cells between the urothelium and lamina propria (the muscle layer) 107, 108 has the benefit of being accurate in terms of cell delivery as well as minimally invasive. An alternative renal grafting approach involves recombination of urothelial cells with embryonic urogenital sinus mesenchyme (UGM) in vitro followed by engraftment under the kidney capsule of recipient hosts 111, 112 . The orthotopic and renal engraftment models are complementary, in that the former enables evaluation of tumour behaviour in an organ-specific microenvironment, whereas the latter is particularly beneficial for investigating the role of epithelial-stromal interactions for tumour growth. Both models have the advantage that gene expression can be manipulated with relative ease in cell culture to introduce gain-or loss-of-function alterations before engraftment, such that the consequences of such alterations for tumour growth can be evaluated in vivo 113 . Notably, engraftment models are not limited to tumour cells; they are adaptable to primary and/or non-transformed cells, which can be particularly beneficial for evaluating gain-of-function mutations, while inclusion of fluorescent or luciferase reporter genes can enable in vivo imaging of tumours and metastases 114, 115 . Orthotopic engraftment models have been used for preclinical evaluation of potential new treatment options, such as the RTK inhibitor sunitinib and inhibition of plasminogen activator inhibitor type 1 (PAI1) (REFS 116, 117) , although these agents have not yet been adapted to clinical practice.
Among the major limitations of engrafted tumours (as well as the patient-derived xenograft (PDX) tumours discussed below) is that they are non-autochthonous, and therefore they do not model the de novo evolution of tumour pheno types. In addition, as recipient hosts are usually immunodeficient, the lack of an intact immune system may impact tumorigenesis as well as metastasis. Nevertheless, engraftment approaches are an excellent starting point to evaluate rapidly the functional importance of candidate genes and to prioritize the generation of GEM models.
PDX models. Engraftment of patient-derived tumour tissues into immunodeficient mouse hosts (called PDX models) has been used increasingly for many types of cancer 118 , and has been described for bladder cancer 119 . As PDX models are derived from individual patient tumours, the expectation is that the resulting tumours capture the unique genomic and molecular properties of the individual patient from whom they are derived. Furthermore, it is expected that PDX models should enable analyses of clinical responses based on the unique characteristics of a given tumour. Indeed, preclinical studies using PDX models of bladder cancer have supported the concept that co-targeting PI3K and MAPK signalling may be beneficial for certain types of bladder cancer 120 . However, few reports to date have described the generation of PDX models for bladder cancer. Thus, it is not clear whether such models can be generated efficiently or whether they will indeed capture all or most bladder cancer subtypes. Conversely, whereas the generation of PDX models for certain types of cancers (such as prostate cancer) may be limited by tissue availability, in principal this should not be a consideration for bladder cancer because primary tissue is available readily from TUR as well as cystectomy. Thus, if bladder cancer has indeed a reasonable 'take-rate' in the recipient hosts, it should be feasible to generate a range of PDX models that, ideally, are representative of the various subtypes of bladder cancer.
GEM models of bladder cancer GEM models are now used widely for many applications in cancer biology, including analyses of tumour phenotypes, modelling disease subtypes, mechanistic investigations of candidate genes and signalling pathways, and preclinical evaluation of potential therapeutic agents [121] [122] [123] . Notably, GEM models complement nonautochthonous mouse models, as tumours arise de novo in the native tissue microenvironment, and they also complement carcinogen-based models, as they are based on defined genetic alterations. However, relatively few GEM models of bladder cancer have been described, particularly those that display muscle-invasive and/or metastatic phenotypes (TABLE 3) , which we believe reflects several major challenges in their design and generation (discussed further, below). In particular, relatively few promoters display bladder-specific expression and can be used to generate GEM models. In addition, bladder tumours seem to be unusually recalcitrant to developing invasive tumours, as most single-gene alterations and even many combined alterations have relatively mild phenotypes (TABLE 3) . However, given the recent description of molecular alterations found in bladder cancer that can be modelled in mice (for example, REF. 32 ), we envision that GEM models are likely to have an increasingly prominent role in the future.
Transgenic models of bladder cancer. Similar to many of the original 'oncomice' 124 , the earliest GEM models of bladder cancer were transgenic mice in which simian virus 40 (SV40) large T antigen is expressed in the urothelium under the control of the uroplakin 2 (Upk2; also known as UPII and UroII) promoter (called UPII-SV40T mice) 125 . The resulting transgenic mice develop CIS and invasive bladder cancer, some progressing to metastasis 125, 126 , and their molecular profiles are conserved with human bladder cancer 127 . A similar phenotype was observed when SV40 large T antigen was expressed under the control of the Krt19 promoter (CK19-SV40T mice) 128 . Interestingly, although SV40 large T antigen inactivates Trp53 and Rb1, combined loss of function of Trp53 and Rb1 is not sufficient for bladder tumours to arise in GEM models 112, 129 . Besides SV40 large T antigen, other oncogenes have been expressed in the urothelium, including Hras, Egfr and cyclin D1 (Ccnd1), with Egfr and Ccnd1 resulting in urothelial hyperplasia; these have also been combined with other alleles, such as mutant Trp53, resulting in progression to dysplasia or non-invasive bladder cancer [130] [131] [132] [133] [134] .
Conditional models of bladder cancer. The majority of recent GEM models of cancer involve tissue-specific conditional or inducible gene targeting. However, the generation of such models for bladder cancer has been challenged by the paucity of Cre alleles that restrict gene targeting specifically to the bladder urothelium and particularly to selected cell types (discussed below) (TABLE 3) . Moreover, most GEM models of bladder cancer described thus far display non-invasive phenotypes. Interestingly, in several cases, GEM models generated using 'bladder-specific' Cre drivers have less aggressive phenotypes than those made using other (non-bladder-specific) Cre drivers (TABLE 3) .
In particular, conditional activation of β-catenin (Ctnnb1) in the bladder using a Cre driver based on the expression of the Upk2 promoter (called UroII-Cre) results in hyperplasia, and together with activation of Hras or Kras or loss of function of Pten, results in papillary non-invasive cancer [135] [136] [137] . However, with an alternative, non-bladder-specific Cre driver, activation of β-catenin alone results in papillary non-invasive cancer 58 (TABLE 3) .
Similarly, abrogation of Notch function by expression of nicastrin (Ncstn) using a bladder-specific promoter results in hyperplasia and CIS, whereas expression of Ncstn using a ubiquitously expressed promoter results in muscleinvasive bladder cancer 138 . Of course, this difference may be due to the actions of Notch outside of the urothelium. Lastly, although loss of function of Pten together with Fgfr3 activation using a UroII-Cre allele results in hyperplasia and localized dysplasia, using alternative non-bladder-specific Cre drivers, Pten loss alone or together with liver kinase B1 (Lkb1; also known as Stk11) results in papillary non-invasive tumours [139] [140] [141] .
Conditional models using adeno-Cre delivery. An alternative to using tissue-specific Cre alleles to target gene recombination in bladder, delivery of Cre-recombinaseexpressing adenovirus (adeno-Cre) directly into the bladder lumen has been used to inactivate Trp53 and Pten in the urothelium, resulting in invasive bladder cancer with prevalent metastasis 112 . This approach has also been used to delete all three members of the RB family, resulting in papillary non-invasive cancer 142 . Interestingly, conditional activation of Kras and inactivation of Trp53 via instillation of adeno-Cre (rather than its surgical injection or delivery into the bladder lumen) results in sarcomas outside the bladder, while the urothelial phenotype is modest 143 . Notably, the adeno-Cre-driven Pten;Trp53 mice display temporal progression from CIS to invasive disease and ultimately develop distant metastasis with high penetrance 112 . Thus, these mice have enabled preclinical investigations comparing intravesical therapy (evaluated at the CIS stage) with systemic therapy (evaluated at more advanced stages) 112, 144, 145 . In particular, comparison of intravesical versus systemic treatment for inhibition of mTOR signalling using rapamycin has demonstrated the efficacy of intravesical therapy 144 ; these findings formed the basis for a clinical trial to evaluate intravesical treatment with rapamycin for high-risk early-stage bladder cancer (see ClinicalTrials.gov identifier: NCT02009332). Similarly, other preclinical studies in this model demonstrated the efficacy of intravesical administration of a multi-chemotherapy regime, which has led to new clinical trials to evaluate intravesical delivery of this treatment for high-risk early-stage bladder cancer (see ClinicalTrials.gov identifier: NCT02202772). These examples suggest that preclinical studies in GEM models that have progressive phenotypes may be advantageous for testing the effectiveness of promising drugs as well as for optimizing the route of their administration.
Opportunities and challenges for GEM models
Compared with other cancer types, bladder cancer is largely underrepresented by GEM models; moreover, the phenotypes of most existing GEM models are primarily non-invasive. Here we discuss major challenges that have impeded the generation of GEM models of bladder cancer and suggest various approaches to overcome these challenges.
Challenges in targeting gene expression to the bladder.
A key consideration for the generation of informative GEM models is the ability to restrict gene targeting to appropriate tissue layers, relevant cell(s) of origin, and to the appropriate stage of tissue development. For bladder, few promoters exist that meet these criteria. In fact, the most widely used is the Upk2 promoter 146 , which can be expressed in other tissues besides bladder, and even within the bladder urothelium is not uniformly expressed but limited primarily to the superficial cells. Of particular concern is that this Upk2 promoter, which is used widely for the generation of transgenic mouse models as well as the development of Cre alleles, has been reported to have been cloned in the wrong orientation 94, 126 , which has potentially compromised its activity and specificity. Recently, the Upk3a promoter has been used to express a tamoxifen-inducible Cre recombinase in the bladder urothelium 20 . Furthermore, as uroplakin is expressed primarily in superficial cells, ideally Cre drivers using these promoters would be complemented by promoters that direct expression to other urothelial cell layers; thus far, promoters that restrict gene targeting specifically to the bladder but preferentially to basal or intermediate cells have not been described. Other promoters that have been used to direct gene expression and/or to express Cre recombinase in the urothelium, although they are not specific for bladder, include fatty acid binding protein 1 (Fabp1), Krt19 and the msh homeobox 2 (Msx2) promoter 58, 128, 147 . In addition, it has been reported that gene recombination specifically in the bladder can be achieved by delivery of tamoxifen directly into the bladder lumen of mice that have tamoxifeninducible Cre alleles 148 ; however, this approach has not been used extensively since this initial report.
In lieu of suitable Cre drivers, an alternative approach to achieve bladder-restricted gene targeting is to introduce an adeno-Cre into the bladder lumen 112, 149 . Adeno-Cre can be delivered intravesically rather than surgically 143 ; however, these mice develop tumours outside the bladder and intravesical delivery is feasible only for female mice, which is a considerable limitation given that bladder cancer is more prevalent in men. Gene recombination via adenoCre has the benefit of being efficient and selective for the urothelium and, because it does not require the generation of mice with an additional Cre allele, can be used to 'screen' the consequences of gene recombination in the bladder 112 . Given that adeno-Cre enables recombination in all the cell layers, it is difficult to evaluate the contribution of specific urothelial cell types, and thus this approach is not ideal for analyses of cell of origin.
Challenges for modelling invasive bladder cancer in mice. A striking difference of modelling bladder cancer in mice compared with modelling other cancers in mice is that relatively few GEM models described so far display overtly invasive or metastatic phenotypes (TABLE 3) . More generally, with few exceptions, dysregulation in the urothelium of individual tumour suppressor genes, such as Rb1, Cdkn1a (which encodes p21), Pten, Trp53, Lkb1 or oncogenes, such as Hras, Kras, Egfr or Fgfr3, have not resulted in invasive bladder cancer, irrespective of the strategy used to direct their expression or induce recombination, although in some cases these dysregulated genes collaborate with others to accelerate bladder cancer phenotypes 112, 126, [129] [130] [131] [133] [134] [135] [136] [139] [140] [141] 150 . Although it is conceivable that the apparent difficulties in generating invasive bladder cancer phenotypes may reflect a lack of 'optimal' targeting approaches or that the models so far have not been based on 'optimal' combinations of genes, considering the numerous examples described thus far (TABLE 3) , it seems likely that the urothelium may be inherently refractory to developing cancer, at least in mice. It is plausible that this reflects the characteristic slow turnover of the urothelium, such that its very limited proliferation renders it resistant to genetic assaults. Indeed, as demonstrated initially for germline loss of function of Trp53 (REF. 151 ), carcinogen treatment, even at sub-carcinogenic doses, exacerbates the bladder tumour phenotypes associated with several genes, including loss of function of Ptch1, Rb1, secreted acidic cysteine rich glycoprotein (Sparc), Cdkn1b (which encodes p27), and gain of function of signal transducer and activator of transcription 3 (Stat3) and insulin-like growth factor 1 (IGF1) 129, [152] [153] [154] [155] [156] [157] [158] . Why might the urothelium be inherently resistant to developing cancer? One possibility is that the current mouse models do not model genomic instability effectively; genomic instability is apparently a distinguishing feature of human bladder cancers (discussed above). Alternatively, or additionally, the current models may not incorporate epigenetic modifications that are prevalent in human bladder cancer, or the 'right' gene combinations to model specific cancer subtypes (discussed above). These are issues that will need to be addressed in future model development.
The future of bladder cancer modelling in mice Historically, research on bladder cancer has lagged considerably behind research on other cancers. This is particularly the case for the generation of mouse models, especially those that represent a spectrum of bladder cancer phenotypes and provide informative preclinical models. As discussed above, the generation of mouse models of bladder cancer has been fraught with inherent difficulties. However, we envision that these challenges are not insurmountable. Considering recent insights regarding the molecular alterations associated with bladder cancer and the description of disease subtypes associated with clinical relevance, the opportunity is now ripe for the exploration of new mouse models and particularly those that can have translatable impact to improve the therapeutic landscape for patients with bladder cancer.
